@DrDDRheum @DrErickZamora1 @hoffmann_vold If you have a normal HRCT and echo does a PFT at same time point add anything? Issues with getting PFTs in covid times #ACR20 @rheumnow @sclerodermaUM

This single slide tries to summarise all major phase3 clinical trials in Psoriatic Arthritis 💪 Take your time. The top half looks at joint efficacy. The bottom half for skin efficacy. #ACR20 https://t.co/FXhJunXNKt

Reducing Immunogenicity of Pegloticase (RECIPE) w/ concomitant use of MMF in pts w/ refractory gout is a phase II double blind RCT that shows sustained serum urate lowering effect in addition to decrease in monthly rate of flares. #ACRbest #Abst0952 @RheumNow Practice changing? https://t.co/Z7GwCXZftE

AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers https://t.co/fRB2zuKl5J #gout #uricosuric a novel uricosuric agent

• AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Ura…

Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect https://t.co/T9IqF7E00Z #OA #DMOAD a potential DMOAD in mice

• Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration…

Next up! #Autoinflammatory diseases: mechanisms and management. First: CRMO & SAPHO with Dr. Polly Ferguson Highlights: 📍The *many* names of CRMO/CNO 📍Clinical features 📍Rx options (NSAIDs, bisphosphonates, TNFi) 📍Role of innate immunity in etiology #ACRambassador https://t.co/qP3IySJKGC

Genotype analysis define new illnesses such as VEXAS. ”Somatic mutation may account for a significant fraction of adult-onset inflammatory disease” says Dr. Dan Castner. Science enthusiasm at 3S038. Autoinflammatory Diseases. @petercgrayson #ACR20 <TK https://t.co/gyTxF8NWtO

Based on RECIPE, how many of you will use MMF concomitantly with start of pegloticase in treating refractory gout patients? #ACR20 @RheumNow

@drdavidliew @VasculitisUMCG @RheumNow Dear David, thanks for your interest in our abstract #ACR20. This is based on some intriguing findings found in our previous observational study https://t.co/HKm53j2xou Still a work in progress but the potential adjunctive anti-inflammatory effect of ARBs seems attractive.

• Treatment with angiotensin II receptor blockers is associated with prolonged re…

Dr. Anthony Fauci at #ACR20 - “We are cautiously optimistic that we will have a safe and effective vaccine at the end of this calendar year and may be able to deploy in individuals with a high risk beginning in early 2021.” @RheumNow

Etanercept monotherapy significantly more effective than Methotrexate monotherapy in maintaining remission in RA patients on combination therapy. Data from the SEAM-RA study @RheumNow #ACR20 Abstr#0939 #ACRbest

Neighbourhood characteristics & socioeconomic factors important not only for contracting #COVID19 but also severe infection in #SLE. Results useful for developing strategies to address socioeconomic stressors in this population. Abs#0984 #ACR20 @RheumNow https://t.co/u4YDcfEcSQ

• Neighborhood Deprivation and Race/Ethnicity Affects COVID-19 Risk and Severity …

Dan Kastner quoting Clement Clark Moore "visions of sugar plums dancing in our heads" looking forward to the new era of molecular taxonomy of rheumatic disease heralded by the discovery of VEXAS #ACR20 @rheumnow

Test your knowledge of day 2 of the #ACR20 meeting. Take our daily ACR IQ quiz and see where you stack up on the leaderboard. https://t.co/8O5vN9Uto5 https://t.co/tx32siM7a3

• https://bit.ly/38kXNtR

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.